X4 PharmaceuticalsXFOR +0.37%29 14-Day RSI is 49.77 as of Jun. 29, 2026. GuruFocus rates XFOR with a GF Score™ of 29/100. The stock has 6 warning signs investors should review. Among 1,422 Biotechnology companies, X4 Pharmaceuticals ranks worse than 60.9% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
X4 Pharmaceuticals 14-Day RSI Related Terms
XFOR vs CMPX, LRMR, PROK: 14-Day RSI Comparison
For the Biotechnology subindustry, X4 Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
X4 Pharmaceuticals 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where X4 Pharmaceuticals's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
X4 Pharmaceuticals (XFOR) has a 14-Day RSI of 49.77 as of Jun. 29, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on X4 Pharmaceuticals and its competitors. According to the industry distribution chart, X4 Pharmaceuticals ranks #866 out of 1422 companies in the Biotechnology industry, placing it in the top 60.9%.
Is X4 Pharmaceuticals' 14-Day RSI too high?
X4 Pharmaceuticals' current 14-Day RSI is 49.77. The Biotechnology industry median 14-Day RSI is 46.00. X4 Pharmaceuticals' value of 49.77 is 8.2% above this industry median. Based on the distribution chart, X4 Pharmaceuticals ranks #866 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, X4 Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' 14-Day RSI compare to CMPX and LRMR?
According to the Biotechnology industry distribution chart, X4 Pharmaceuticals ranks #866 out of 1422 companies for 14-Day RSI. This places X4 Pharmaceuticals in the lower half of its industry. The industry median 14-Day RSI is 46.00. X4 Pharmaceuticals' value of 49.77 is 8.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 46.00, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. X4 Pharmaceuticals's current 14-Day RSI of 49.77 is 8.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on X4 Pharmaceuticals and its competitors. For the Biotechnology industry, the median 14-Day RSI is 46.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. X4 Pharmaceuticals's current 14-Day RSI is 49.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current 14-Day RSI of 49.77. The current 14-Day RSI is 49.77 and 8.2% above the Biotechnology industry median of 46.00. X4 Pharmaceuticals' overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current 14-Day RSI is 49.77 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
29GF Score
Get the complete analysis for XFOR
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XFOR has been successfully added to your 